Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Helga Rübsamen‐Schaeff"'
Autor:
Dirk Kropeit, Susanne Bonsmann, Oliver von Richter, David McCormick, Jörg Pausch, Melanie Sumner, Alexander Birkmann, Holger Zimmermann, Helga Rübsamen‐Schaeff
Publikováno v:
Clinical Pharmacology in Drug Development.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c5887c1fe383470f851d2912aa34596
https://doi.org/10.1002/cpdd.1241
https://doi.org/10.1002/cpdd.1241
Autor:
Helga Rübsamen‐Schaeff
Publikováno v:
New Drug Development for Known and Emerging Viruses. :151-174
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f2db713c08492102a956f21c610a07d
https://doi.org/10.1002/9783527810697.ch6
https://doi.org/10.1002/9783527810697.ch6
Autor:
Holger Zimmermann, Katharina Erb-Zohar, Dirk Kropeit, Helga Rübsamen-Schaeff, Jochen G W Theis, Hans-Peter Stobernack, Jürgen Scheuenpflug, David McCormick
Publikováno v:
Clinical Pharmacology in Drug Development. 11:6-15
Letermovir is a human cytomegalovirus (CMV) terminase inhibitor approved in the United States, Canada, Japan, and the European Union for prophylaxis of CMV infection and disease in CMV-seropositive, allogeneic, hematopoietic stem-cell transplant reci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f276ca77abc2db5660ed2a77f8643bef
https://doi.org/10.1002/cpdd.1043
https://doi.org/10.1002/cpdd.1043
Autor:
Helga Rübsamen-Schaeff
Publikováno v:
Pure and Applied Chemistry. 91:717-728
This contribution describes the experiences with three careers: leading and building an academic research institute, heading a research area in a multinational pharma company and founding and leading a biotech company, which saw its first drug succes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::718ca6a00ec9eb4a47e97a8a59ce5e7d
https://doi.org/10.1515/pac-2018-1105
https://doi.org/10.1515/pac-2018-1105
Autor:
Detlev Ganten, Susanna Palkonen, Valentin Fuster, Bente Stallknecht, Ulf Smith, Laurent Degos, Michael Manns, Karin R. Sipido, Dainius Pavalkis, Fernando Antoñanzas, Tomáš Zima, Stephen T. Holgate, Richard S. J. Frackowiak, Hans Hofstraat, Helga Rübsamen-Schaeff, Julio Celis, Françoise Meunier, Gabriel P. Krestin, Wolfgang H. Oertel
Publikováno v:
The Lancet
Lancet (UK), 395(10242), 1970-1971. Elsevier Ltd.
RIUR. Repositorio Institucional de la Universidad de La Rioja
instname
Lancet (UK), 395(10242), 1970-1971. Elsevier Ltd.
RIUR. Repositorio Institucional de la Universidad de La Rioja
instname
ispartof: LANCET vol:395 issue:10242 pages:1970-1971 ispartof: location:England status: published
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c189b129ce7ddc73c231961b896728c4
https://investigacion.unirioja.es/documentos/5f1cd7e929995265e44d0ee1
https://investigacion.unirioja.es/documentos/5f1cd7e929995265e44d0ee1
Discusses how to fight Ebola, SARS Corona, and other known or emerging human viruses by building on the successes in antiviral therapy of the past decades Written by leading medicinal chemists from academia and industry, this book discusses the entir
Autor:
Valentin S. Moiseev, David McCormick, Holger Zimmermann, Dirk Kropeit, Zhanna Kobalava, Katharina Erb-Zohar, Hans-Peter Stobernack, Helga Rübsamen-Schaeff
Publikováno v:
British Journal of Clinical Pharmacology. 83:2678-2686
Aims Human cytomegalovirus constitutes a prevalent and serious threat to immunocompromised individuals and requires new treatments. Letermovir is a novel viral-terminase inhibitor that has demonstrated prophylactic/pre-emptive activity against human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10feb9d01e71ea92d125e6d5f3495f31
https://doi.org/10.1111/bcp.13376
https://doi.org/10.1111/bcp.13376
Autor:
Katharina Erb-Zohar, David McCormick, Helga Rübsamen-Schaeff, Holger Zimmermann, Hans-Peter Stobernack, Dirk Kropeit
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(1)
Letermovir is a human cytomegalovirus (CMV) terminase inhibitor for the prophylaxis of CMV infection and disease in allogeneic hematopoietic stem-cell transplant recipients. In vitro studies have identified letermovir as a potential cytochrome P450 (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9316c1200ae6f122f1b928345d93edec
https://pubmed.ncbi.nlm.nih.gov/34714967
https://pubmed.ncbi.nlm.nih.gov/34714967
Autor:
Helga Rübsamen-Schaeff, Andreas Weishaupt, Daniela Paulsen, Niklas Beyersdorf, Sandra Werner, Nelli Wolf, Gabriele Köllner, Thomas Kerkau, Thomas Hünig
Publikováno v:
Journal of Neuroimmunology. 282:63-72
Targeting regulatory T cells (Treg cells) with interleukin-2 (IL-2) constitutes a novel therapeutic approach for autoimmunity. As anti-cancer therapy with IL-2 has revealed substantial toxicities a mutated human IL-2 molecule, termed AIC284 (formerly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::707789e066ff905a3450b4352d35bf4b
https://doi.org/10.1016/j.jneuroim.2015.03.020
https://doi.org/10.1016/j.jneuroim.2015.03.020
Autor:
Egj Hulskotte, H-P Stobernack, Dirk Kropeit, Katharina Erb-Zohar, Holger Zimmermann, Helga Rübsamen-Schaeff, J Scheuenpflug, A van Schanke
Publikováno v:
Clinical and Translational Science
Letermovir is a novel antiviral in clinical development for prophylaxis against human cytomegalovirus in immunocompromised transplant recipients. This two‐part, single‐center, randomized, double‐blind, placebo‐controlled trial evaluated the s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::676b9d59c465c31e382e0bc80b40c3c4
https://pubmed.ncbi.nlm.nih.gov/28675594
https://pubmed.ncbi.nlm.nih.gov/28675594